Apollo Hospitals reported 21% revenue growth for Q1 FY27, outperforming Max Healthcare, which is managing margin pressure from aggressive expansion. While Apollo focuses on its pharmacy demerger, Max Healthcare faces rising debt and capacity integration costs. Their stock performances over the last year have diverged, with Apollo gaining 10% compared to a 17.5% decline for Max Healthcare.
In the recently concluded June quarter (Q1 FY27), India's two major hospital chains reported contrasting performances that highlight different growth strategies. Apollo Hospitals delivered a 21% year-on-year growth in consolidated revenue, outperforming Max Healthcare, which reported revenue growth of approximately 15.3% to 16%.
Apollo Hospitals’ performance was driven by an 11% increase in patient volumes and an 8% rise in the average revenue per patient (ARPP). This, combined with better cost management, led to an operating profit margin of 15.5%, an improvement of 92 basis points compared to the previous year. For investors, a key event remains the upcoming demerger of its pharmacy and digital health business, Apollo HealthCo. The company expects this to unlock shareholder value, with the listing targeted around the fourth quarter of the current financial year.
In contrast, Max Healthcare is currently in a phase of heavy capital spending. The company plans to add approximately 2,800 beds over the next two years, requiring an outlay of ₹6,100 crore. This aggressive expansion has put pressure on its financials. Max Healthcare’s operating profit margin contracted to about 24.6% during the quarter, as the company absorbed costs related to new capacity and integration. Furthermore, its net debt has risen to ₹2,384 crore as of June 30, 2026.
The market reaction to these differing strategies has been distinct over the past year. Apollo Hospitals’ stock has gained roughly 10%, while Max Healthcare’s shares have seen a decline of approximately 17.5%. While both companies are growing, they are at different stages of their business cycles. Apollo is benefiting from more established facilities, while Max Healthcare is dealing with the immediate cash flow and margin impact of its large-scale expansion projects.
Investors should note that both companies face sector-wide risks, including potential regulatory changes like price caps on private hospital services. For Max Healthcare, the primary risk involves execution—managing the rising debt load while ensuring that the new beds contribute to profits as planned. For Apollo, the challenge remains keeping its newer hospitals on track to break even, with targets set for the 2028 financial year. The key monitorables for the next few quarters will be the progress of the demerger for Apollo and the debt-to-profitability trend for Max Healthcare.